Steven D. Hume, Owensboro, KY (US); Leigh Burden, Owensboro, KY (US); Joshua Morton, Evansville, IN (US); Greg Pogue, Austin, TX (US); Barry Bratcher, Owensboro, KY (US); Hugh A. Haydon, Louisville, KY (US); Carrie A. Simpson, Evansville, IN (US); Nick Partain, Owensboro, KY (US); Youngjun Oh, Owensboro, KY (US); John W. Shepherd, Owensboro, KY (US); and Michael H. Pauly, Del Mar, CA (US)
Assigned to KBIO HOLDINGS LIMITED, London (GB)
Filed by KBIO HOLDINGS LIMITED, London (GB)
Filed on Jul. 2, 2020, as Appl. No. 16/919,943.
Application 16/919,943 is a continuation in part of application No. 16/709,063, filed on Dec. 10, 2019.
Application 16/709,063 is a continuation in part of application No. 16/437,734, filed on Jun. 11, 2019.
Claims priority of provisional application 62/683,865, filed on Jun. 12, 2018.
Claims priority of provisional application 63/013,284, filed on Apr. 21, 2020.
Prior Publication US 2021/0000942 A1, Jan. 7, 2021
1. An antigen, comprising: a fusion peptide having a first peptide which comprises a receptor binding domain of a pathogen, and a second peptide wherein the fusion peptide is capable of being chemically linked with a virus particle, and wherein the second peptide is a fragment crystallizable (Fc) region of an antibody capable of binding to a Fc receptor.